Ozempic lawsuit: gastroparesis and GLP-1 receptor agonist claims

Why GLP-1 litigation is a defining mass tort

The rapid rise of GLP-1 receptor agonist medications -- including semaglutide (Ozempic and Wegovy) and liraglutide (Saxenda and Victoza) -- has been accompanied by growing reports of severe gastrointestinal injuries that manufacturers allegedly failed to adequately warn about. Gastroparesis, bowel obstruction, pancreatitis, and gallbladder disease have been reported by thousands of patients, leading to an emerging wave of product liability litigation against Novo Nordisk and Eli Lilly.

Millions of Americans have been prescribed these medications for diabetes management and weight loss. By 2024, more than 40 million GLP-1 prescriptions were dispensed annually in the United States. Novo Nordisk's revenue from semaglutide products exceeded $21 billion in 2023. This enormous patient population means the potential plaintiff pool is exceptionally large.

GLP-1 receptor agonist litigation is emerging as a defining mass tort of this decade. The combination of massive prescription volumes, a well-understood injury mechanism, growing adverse event data, and allegations of inadequate warnings creates a compelling litigation framework.

Understanding GLP-1 receptor agonist medications

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, stimulating insulin secretion, reducing glucagon production, slowing gastric emptying, and promoting satiety. The delayed gastric emptying effect -- while therapeutically useful for appetite suppression -- is the mechanism that causes gastroparesis and other gastrointestinal injuries.

Semaglutide products

Ozempic (FDA-approved December 2017 for type 2 diabetes) is widely prescribed off-label for weight loss. Wegovy (approved June 2021 for chronic weight management) uses higher doses up to 2.4 mg, which may increase GI adverse event risk. Rybelsus (approved September 2019) is the oral tablet form.

Tirzepatide products

Tirzepatide, manufactured by Eli Lilly, is a dual GIP/GLP-1 receptor agonist sold as Mounjaro (approved May 2022 for diabetes) and Zepbound (approved November 2023 for weight management). Its gastrointestinal side effect profile is similar to semaglutide, making Eli Lilly a co-defendant.

How GLP-1 agonists cause gastrointestinal injuries

The mechanism of injury is directly related to the therapeutic action of these drugs. GLP-1 receptor agonists slow gastric emptying as their designed effect, but in some patients this becomes pathological -- the stomach cannot empty adequately, resulting in gastroparesis that can become chronic and persist after discontinuation.

Intestinal dysmotility and bowel obstruction

GLP-1 receptors throughout the GI tract reduce intestinal motility, potentially causing bowel obstruction, ileus, and severe constipation requiring surgical intervention. The American Society of Anesthesiologists issued 2023 guidance warning of aspiration risk during anesthesia in GLP-1 patients.

Pancreatic and gallbladder effects

Chronic overstimulation of pancreatic cells may trigger pancreatitis and potentially increase pancreatic cancer risk. GLP-1 agonists have been associated with gallstones, cholecystitis, and choledocholithiasis due to reduced gallbladder motility and altered bile composition.

Gastroparesis: the central injury in Ozempic litigation

Gastroparesis -- stomach paralysis -- is the primary injury driving GLP-1 litigation. Patients experience persistent nausea, vomiting of undigested food, severe abdominal pain, early satiety, weight loss, malnutrition, and erratic blood glucose levels. A critical allegation is that GLP-1-induced gastroparesis can become chronic, persisting long after the medication is stopped. While Novo Nordisk's prescribing information acknowledges delayed gastric emptying, plaintiffs allege the labels did not adequately warn that this effect could become permanent.

Qualifying injuries and claim types

FDA adverse event reports and regulatory actions

The FDA Adverse Event Reporting System (FAERS) has received tens of thousands of reports related to semaglutide products. In September 2023, the FDA updated Ozempic's prescribing information to add "ileus" as a reported adverse reaction -- a significant acknowledgment that plaintiffs argue came too late. Ongoing FDA safety reviews examine aspiration during anesthesia, suicidal ideation reports, and pancreatitis and thyroid cancer signals.

The failure-to-warn legal theory

The primary legal theory is that manufacturers did not adequately warn about the risk of gastroparesis as a persistent and potentially permanent condition, the severity of gastrointestinal symptoms, the risk of bowel obstruction and ileus (until the 2023 label update), and the possibility that effects might persist after discontinuation.

The learned intermediary exception

The extensive direct-to-consumer advertising campaigns for Ozempic and Wegovy may create an exception to the learned intermediary doctrine. DTC marketing minimized side effects while emphasizing weight loss benefits, potentially circumventing the defense. Some plaintiffs also pursue design defect claims, arguing GLP-1 agonists are unreasonably dangerous for weight loss patients.

MDL 3094 and current litigation status

In August 2023, the JPML created MDL No. 3094, In re: Ozempic (Semaglutide) and Mounjaro (Tirzepatide) Products Liability Litigation, consolidating federal GLP-1 cases in the Eastern District of Pennsylvania. The MDL includes thousands of pending cases with new filings continuing rapidly. Early discovery focuses on internal documents regarding knowledge of GI risks, clinical trial data on gastroparesis rates, and warning label adequacy.

Defendants: Novo Nordisk and Eli Lilly

Both defendants have enormous financial resources and have retained top defense firms. Their primary strategy centers on arguing that GLP-1 labels adequately warned about GI side effects and that individual conditions were caused by other factors. Plaintiff attorneys should prepare for well-funded, aggressive defense litigation.

Settlement projections and case valuation

Building a strong Ozempic case

Effective case building requires pharmacy fill records documenting the specific GLP-1 medication, dosage, and dates of use. Medical records documenting the injury -- gastric emptying study results, imaging for bowel obstruction, lab results for pancreatitis, surgical records -- are essential. Pre-GLP-1 medical records demonstrating normal GI function before starting the medication strengthen causation arguments significantly.

Medical causation strategy

General causation is strongly supported by the known pharmacology -- delayed gastric emptying is a designed effect. Gastroenterologists provide specific causation via differential diagnosis. Pharmacologists explain the dose-response relationship and why higher doses carry greater risk. The FDA's inclusion of ileus in the Ozempic label and the volume of FAERS reports support both general and specific causation.

How to acquire Ozempic claimants

SEM campaigns targeting "Ozempic lawsuit," "Ozempic gastroparesis lawyer," and "GLP-1 stomach paralysis" reach individuals actively seeking legal counsel. Pre-qualified Ozempic leads from Mass Tort Agency offer a direct pipeline. Patient community outreach through weight loss forums and social media groups, healthcare provider referrals from gastroenterologists and endocrinologists, and content marketing about GLP-1 side effects build additional acquisition channels.

Cross-referencing related practice areas

GLP-1 litigation pairs well with other pharmaceutical and product liability mass torts. Firms active in this area may benefit from diversifying into Camp Lejeune water contamination, AFFF firefighting foam, or Roundup cancer claims for revenue stability and a broader client base.